Trial Profile
A Randomized, Double-Blind, Two-Way Crossover Study to Determine the Bioequivalence of a Single Dose of Testim 1% With Pentadecalactone 1% Relative to a Single Dose of Testim 1% With Pentadecalactone 8% in Hypogonadal Males
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Auxilium Pharmaceuticals
- 03 Apr 2022 Status changed from recruiting to completed.
- 18 Aug 2011 New trial record